Company Overview and News

5
AltaGas sells 35% of B.C. hydroelectric operation for $922 million

2018-06-13 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C ALA.PR.B ALA.PR.A ALA.PR.I MFC ATGFF ALA.PR.G 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
UPDATE 1-AltaGas sells 35 pct stake in hydro projects for C$922 mln

2018-06-13 reuters
June 13 (Reuters) - Canadian utility AltaGas Ltd said on Wednesday it would sell a 35 percent stake in three hydroelectric projects in Northwest British Columbia for C$922 million ($707.87 million) to help fund its acquisition of U.S.-based WGL Holdings Inc.
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C WGL ALA.PR.B ALA.PR.A ALA.PR.I MFC ALA.PR.G ATGFF 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
AltaGas sells 35 pct stake in hydro projects for C$922 mln

2018-06-13 reuters
June 13 (Reuters) - Canadian utility AltaGas Ltd said on Wednesday it would sell a 35 percent stake in the Northwest British Columbia Hydro Electric Facilities for C$922 million ($707.87 million).
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C WGL ALA.PR.B ALA.PR.A ALA.PR.I MFC ATGFF ALA.PR.G 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

0
BRIEF-Altagas and WGL Holdings Announce Settlement In Principle With Key Stakeholders In Washington D.C.

2018-05-04 reuters
* ALTAGAS LTD. AND WGL HOLDINGS, INC. ANNOUNCE A SETTLEMENT IN PRINCIPLE WITH KEY STAKEHOLDERS IN WASHINGTON D.C.
ALA.PR.I ATGFF ALA.PR.G ALA.PR.U ALA.PR.E ALA.PR.B ALA.PR.A ALA

30
WGL Holdings-AltaGas Merger Gets Another Regulatory Approval

2018-04-06 zacks
WGL Holdings, Inc (WGL - Free Report) announced the receipt of approval from Maryland Public Service Commission for its merger with AltaGas Ltd. (ALA.TO). The merger is valued at $4.5 billion. Subject to approval from the Public Service Commission of District of Columbia, the merger, which was announced on Jan 25, 2017, is expected to be completed by the first half of 2018. Approval Subject to Conditions Maryland Public Service Commission’s approval for the merger of the complementary energy companies is subject to the fulfillment of certain conditions.
WFCNP SCG ALA.PR.U WGL WFC.PRL WFC.PRJ WFC.PRT WFC.PRR ATGFF WFC.PRQ WFC.PRP WFC.PRO UBS WFC.PRN SCU UBS.PRDCL WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS NJR ALA.PR.B ALA.PR.A ALA.PR.I ALA.PR.G ALA.PR.E ALA ULSGF

0
BRIEF-AltaGas And WGL Holdings, Inc. Announce Approval Of Merger By The Maryland Public Service Commission

2018-04-04 reuters
* ALTAGAS AND WGL HOLDINGS, INC. ANNOUNCE APPROVAL OF MERGER BY THE MARYLAND PUBLIC SERVICE COMMISSION
ALA.PR.I ATGFF ALA.PR.G ALA.PR.U ALA.PR.E ALA.PR.B ALA.PR.A ALA

0
Birchcliff Energy Ltd. and Altagas Ltd. Announce New Long-Term Processing Arrangement at Altagas’ Deep-Cut Processing Facility in Gordondale

2018-04-03 globenewswire
CALGARY, Alberta, April 03, 2018 (GLOBE NEWSWIRE) -- Birchcliff Energy Ltd. (“Birchcliff”) (TSX:BIR) and AltaGas Ltd. (“AltaGas”) (TSX:ALA) are pleased to announce that they have entered into a definitive agreement for a long-term natural gas processing arrangement (the “Processing Arrangement”) at AltaGas’ deep-cut sour gas processing facility located in Gordondale, Alberta (the “Gordondale Facility”).
ALA.PR.I BIR ATGFF ALA.PR.G BIREF ALA.PR.U ALA.PR.E ALA.PR.B ALA.PR.A ALA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

9h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...